Key result
In patients with acute coronary syndrome, achieving a discharge resting heart rate of less than 65 bpm with beta-blocker therapy significantly reduced major adverse cardiac events at 24 months to 9.1% compared to higher heart rates.
Cohort (n=912)
Yes
Cardiac ischemia can manifest across a disease spectrum including unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI). These unstable ischemic conditions are described clinically as Acute Coronary Syndrome (ACS). Typically, the ischemia associated with ACS is the result of atherosclerotic changes of the coronary arteries, which can eventually lead to acute or chronic vessel occlusion. Coronary artery disease is the leading cause of morbidity and mortality in the United States with ACS accounting for more than 1.6 million hospital admissions per year. The estimated economic burden of ACS is 150 billion dollars annually
No takes yet. Share an insight, caveat, or question.
Kumar Amruthlal Jain (2014) conducted a cohort in Acute Coronary Syndrome (n=912). Beta-blocker therapy achieving discharge resting heart rate <65 bpm vs. Discharge resting heart rate ≥65 bpm was evaluated on Major Adverse Cardiac Events (MACE) at 24 months (p=0.002). In patients with acute coronary syndrome, achieving a discharge resting heart rate of less than 65 bpm with beta-blocker therapy significantly reduced major adverse cardiac events at 24 months to 9.1% compared to higher heart rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: